Arcus Biosciences, Inc , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
infoArcus Biosciences is a small cap stock with a total market cap of 1.72B.
infoThey trade on the NYSE and had their IPO 5 years and 5 months ago.
infoArcus Biosciences currently employs 500 people.
infoAs of Wednesday, Aug 23 2023, Arcus Biosciences’s share price is $23.03.
News Relating to Arcus Biosciences
Proactive Investors
Stock movers: Nvidia, iTeos, Arcus, Manchester United, Nike, AMC, Bath & Body Works and more
Wednesday Aug 23 2023 at 13:46
Nvidia: calm before the storm There’s a calm before storm ahead of today’s hotly-anticipated quarterly financials, albeit Nvidia stock is up US$9.17 or 2% changing hands at US$465.75. Expectations are set exceptionally high in the market, after May’s outperformance rocketed Nvidia into the ‘trillion dollar club’, volatility will likely ensue later today as the numbers drop.
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
Monday Aug 07 2023 at 10:38
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.93 per share a year ago.
MarketBeat
3 Biotech Stocks to Buy for Long-Term Gains
Thursday Jul 13 2023 at 07:01
Suppose you’re looking for a sector that will benefit from an end to the Federal Reserve’s interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated assets, meaning their value is sensitive to changes in interest rates.
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
Tuesday May 09 2023 at 19:52
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.96 per share a year ago.
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Tuesday Feb 28 2023 at 18:49
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Buy 3 Top Profitable Stocks Using Net Income Ratio
Tuesday Feb 14 2023 at 08:17
Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio.
Zacks Investment Research
Down -45.21% in 4 Weeks, Here’s Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround
Thursday Jan 12 2023 at 11:18
The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Proactive Investors
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectations
Tuesday Dec 20 2022 at 11:51
Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer drug combinations. The results showed the program is viable but left investors questioning how the pair and their proposed therapeutic could compete against other more established companies in the tough research and development space.
Market Watch
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug
Tuesday Dec 20 2022 at 08:47
Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that it’s developing with Gilead Sciences Inc. GILD, -0.39% improved progression-free survival and overall response rate [ORR] in a Phase 2 clinical study. “The data clearly show that the program is viable, keeping hope alive for active building blocks within the large lung cancer space, but numerical ORR may be disappointing to some and it remains to be seen how much GILD/RCUS’s combo can truly differentiate vs.
Zacks Investment Research
Wall Street Analysts Believe Arcus Biosciences, Inc. (RCUS) Could Rally 45%: Here’s is How to Trade
Tuesday Nov 29 2022 at 11:17
The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Investors Business Daily
Gilead’s Cancer Program Notches Another Win, But It’s Arcus Stock That Surges
Monday Nov 28 2022 at 12:27
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. The post Gilead’s Cancer Program Notches Another Win, But It’s Arcus Stock That Surges appeared first on Investor’s Business Daily.
Zacks Investment Research
Buy 3 of the Best Stocks by Using Net Income Ratio
Friday Nov 04 2022 at 09:02
Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Wednesday Nov 02 2022 at 18:50
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Wednesday Aug 24 2022 at 16:05
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences: Citi 17th Annual BioPharma Conference Date: Wednesday, September 7th, 2022 Location: Boston, MA Format: 1-on-1 meetings only Morgan Stanley 20th Annual Global Healthcare Conference Date:
Business Wire
Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Tuesday May 31 2022 at 16:05
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California. The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT. A liv
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Monday May 09 2022 at 19:33
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates
Wednesday Feb 23 2022 at 19:58
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Friday Jan 07 2022 at 05:21
Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Stockmarketcom
4 Biotech Stocks To Watch This Week
Monday Nov 22 2021 at 13:58
Could these biotech stocks be poised for long-term gains?
The Motley Fool
Why Arcus Biosciences Stock Is On Fire Today
Thursday Nov 18 2021 at 08:44
Gilead Sciences has decided to exercise its options for three of the biotech’s oncology programs.
Pulse2
Arcus Biosciences (RCUS) Stock: Why The Price Jumped Today
Thursday Nov 18 2021 at 08:03
The stock price of Arcus Biosciences Inc (NYSE: RCUS) increased by over 10% pre-market today. This is why it happened.
Market Watch
Arcus Biosciences shares rocket premarket after Gilead exercises options for 3 cancer programs for $725 million
Thursday Nov 18 2021 at 07:38
Shares of Arcus Biosciences Inc. RCUS, -1.10% rocketed 21% in premarket trading Thursday, after Gilead Sciences Inc. GILD, +0.85% said it’s exercising options to three programs in the company’s clinical-stage portfolio for payments of $725 million. The programs in question include anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat, treatments for different cancers.
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Monday Nov 08 2021 at 19:54
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 1.77% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Monday Sep 27 2021 at 16:10
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 58,200 shares of the Company’s common stock at an exercise price per share of $36.99, which was the closing price on September 23, 2021. The stock options were granted pursuant to the Compa
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Thursday Sep 09 2021 at 16:10
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 44,200 shares of the Company’s common stock at an exercise price per share of $34.31, which was the closing price on September 8, 2021. The stock options were granted pursuant to the Compan
Business Wire
Arcus Biosciences to Participate at Upcoming Investor Conferences
Wednesday Sep 01 2021 at 16:10
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences. Citi’s 16th Annual Virtual Biopharma Conference, Friday, September 10 at 1:25 pm ET 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27 at 4:40 pm ET A live audio webcast of the presentation will b
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
Tuesday Aug 24 2021 at 16:10
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted twelve new employees options to purchase a total of 104,200 shares of the Company’s common stock at an exercise price per share of $29.35, which was the closing price on August 23, 2021. The stock options were granted pursuant to the Compan
Seeking Alpha
Arcus Biosciences, Inc. (RCUS) CEO Terry Rosen on Q2 2021 Results – Earnings Call Transcript
Saturday Aug 07 2021 at 16:37
Arcus Biosciences, Inc. (RCUS) CEO Terry Rosen on Q2 2021 Results – Earnings Call Transcript
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates
Thursday Aug 05 2021 at 22:03
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulse2
RCUS Stock Increased 8.03%: Why It Happened
Tuesday Jul 20 2021 at 20:04
The stock price of Arcus Biosciences Inc (NYSE: RCUS) increased by 8.03% today. This is why it happened.
Arcus Biosciences Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Arcus Biosciences’s Altman Z-score is 0.7 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Arcus Biosciences Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $911.25K of common stock in Arcus Biosciences on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Arcus Biosciences’s Income Quality of 0.82 is greater than its Industry Group of 0.69 (18.8% greater)
Arcus Biosciences’s Income Quality of 0.82 is greater than its Major Industry Group of 0.71 (15.5% greater)
Arcus Biosciences’s Income Quality of 0.82 is in line with its Sector of 0.75 (9.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Arcus Biosciences’s Current Ratio of 5.48 is greater than its Industry Group of 4.76 (15.1% greater)
Arcus Biosciences’s Current Ratio of 5.48 is greater than its Major Industry Group of 4.32 (26.9% greater)
Arcus Biosciences’s Current Ratio of 5.48 is greater than its Sector of 2.6 (110.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-6.08 & -1.27)
Cannot compare a negative PE Ratio (-6.08 & -1.1)
Cannot compare a negative PE Ratio (-6.08 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Arcus Biosciences’s PB Ratio of 3.03 is greater than its Industry Group of 1.34 (126.1% greater)
Arcus Biosciences’s PB Ratio of 3.03 is greater than its Major Industry Group of 1.4 (116.4% greater)
Arcus Biosciences’s PB Ratio of 3.03 is greater than its Sector of 1.62 (87.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Arcus Biosciences’s ROE of -0.5 is lower than its Industry Group of -0.44 (-13.6% lower)
Arcus Biosciences’s ROE of -0.5 is lower than its Major Industry Group of -0.38 (-31.6% lower)
Arcus Biosciences’s ROE of -0.5 is lower than its Sector of -0.03 (-1566.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Arcus Biosciences’s ROCE of -0.3 is greater than its Industry Group of -0.42 (28.6% greater)
Arcus Biosciences’s ROCE of -0.3 is greater than its Major Industry Group of -0.37 (18.9% greater)
Arcus Biosciences’s ROCE of -0.3 is lower than its Sector of -0.04 (-650.0% lower)
Derived from SEC.GOV filing dataopen_in_new